Healthcare - Medical - Diagnostics & Research - NYSE - US
$ 235.21
-1.25 %
$ 19.7 B
Market Cap
44.72
P/E
Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests.[ Read More ]
The intrinsic value of one LH stock under the base case scenario is HIDDEN Compared to the current market price of 235 USD, Laboratory Corporation of America Holdings is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart LH
FINANCIALS
12.2 B
REVENUE
726 M
OPERATING INCOME
379 M
NET INCOME
1.33 B
OPERATING CASH FLOW
-1.17 B
INVESTING CASH FLOW
-59.3 M
FINANCING CASH FLOW
3.28 B
REVENUE
254 M
OPERATING INCOME
170 M
NET INCOME
277 M
OPERATING CASH FLOW
-579 M
INVESTING CASH FLOW
1.55 B
FINANCING CASH FLOW
Balance Sheet Decomposition
Laboratory Corporation of America Holdings
| Current Assets | 3.77 B |
| Cash & Short-Term Investments | 537 M |
| Receivables | 2.1 B |
| Other Current Assets | 1.13 B |
| Non-Current Assets | 13 B |
| Long-Term Investments | 26.9 M |
| PP&E | 2.91 B |
| Other Non-Current Assets | 10 B |
| Current Liabilities | 3.23 B |
| Accounts Payable | 828 M |
| Short-Term Debt | 1.34 B |
| Other Current Liabilities | 1.05 B |
| Non-Current Liabilities | 5.61 B |
| Long-Term Debt | 4.78 B |
| Other Non-Current Liabilities | 827 M |
EFFICIENCY
Earnings Waterfall
Laboratory Corporation of America Holdings
| Revenue | 12.2 B |
| Cost Of Revenue | 8.8 B |
| Gross Profit | 3.36 B |
| Operating Expenses | 2.02 B |
| Operating Income | 726 M |
| Other Expenses | 346 M |
| Net Income | 379 M |
RATIOS
27.67%
GROSS MARGIN
5.97%
OPERATING MARGIN
3.44%
NET MARGIN
5.31%
ROE
2.50%
ROA
3.70%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Laboratory Corporation of America Holdings
| Net Income | 379 M |
| Depreciation & Amortization | 577 M |
| Capital Expenditures | -454 M |
| Stock-Based Compensation | 129 M |
| Change in Working Capital | -362 M |
| Others | 439 M |
| Free Cash Flow | 874 M |
Wall Street Analysts Price Targets
Laboratory Corporation of America Holdings
Wall Street analysts predict an average 1-year price target for LH of $257 , with forecasts ranging from a low of $240 to a high of $277 .
LH Lowest Price Target
Wall Street Target
240 USD
2.04%
LH Average Price Target
Wall Street Target
257 USD
9.19%
LH Highest Price Target
Wall Street Target
277 USD
17.77%
4. DIVIDEND ANALYSIS
0.32%
DIVIDEND YIELD
0.72 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Laboratory Corporation of America Holdings
Sold
0-3 MONTHS
2.19 M USD 3
3-6 MONTHS
6.36 M USD 3
6-9 MONTHS
12.7 M USD 7
9-12 MONTHS
392 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
6 days ago
Nov 11, 2024
|
Sell 1.51 M USD
|
Schechter Adam H
President & CEO |
- 6189
|
243.47 USD |
|
3 weeks ago
Oct 24, 2024
|
Sell 230 K USD
|
ANDERSON KERRII B
Director |
- 1000
|
230 USD |
|
2 months ago
Aug 19, 2024
|
Sell 454 K USD
|
van der Vaart Sandra D
EVP, Chief Legal Officer |
- 2000
|
227.05 USD |
|
3 months ago
Aug 15, 2024
|
Sell 663 K USD
|
EISENBERG GLENN A
Chief Financial Officer, EVP |
- 2979
|
222.6494 USD |
|
3 months ago
Aug 15, 2024
|
Sell 660 K USD
|
EISENBERG GLENN A
Chief Financial Officer, EVP |
- 2950
|
223.6169 USD |
|
3 months ago
Aug 15, 2024
|
Sell 2.04 M USD
|
EISENBERG GLENN A
Chief Financial Officer, EVP |
- 9071
|
224.5488 USD |
|
3 months ago
Aug 07, 2024
|
Sell 93.2 K USD
|
ANDERSON KERRII B
Director |
- 414
|
225 USD |
|
3 months ago
Aug 08, 2024
|
Sell 132 K USD
|
ANDERSON KERRII B
Director |
- 586
|
225 USD |
|
3 months ago
Aug 05, 2024
|
Sell 516 K USD
|
BERBERIAN LANCE
EVP, CIO & CTO |
- 2245
|
229.785 USD |
|
3 months ago
Aug 05, 2024
|
Sell 2.25 M USD
|
BERBERIAN LANCE
EVP, CIO & CTO |
- 9848
|
228.9485 USD |
|
6 months ago
May 14, 2024
|
Sell 379 K USD
|
van der Vaart Sandra D
EVP, Chief Legal Officer |
- 1800
|
210.8268 USD |
|
6 months ago
May 14, 2024
|
Sell 42.2 K USD
|
van der Vaart Sandra D
EVP, Chief Legal Officer |
- 200
|
210.835 USD |
|
6 months ago
Apr 30, 2024
|
Sell 51 K USD
|
ANDERSON KERRII B
Director |
- 250
|
204.135 USD |
|
6 months ago
May 02, 2024
|
Sell 50 K USD
|
ANDERSON KERRII B
Director |
- 250
|
200.0981 USD |
|
6 months ago
Apr 29, 2024
|
Sell 498 K USD
|
Wilkinson Peter J
SVP, Chief Accounting Officer |
- 2439
|
204.329 USD |
|
7 months ago
Apr 01, 2024
|
Sell 1.41 M USD
|
Schroeder Mark S
EVP, Pres Diagnostics & COO |
- 6477
|
217.29 USD |
|
7 months ago
Apr 01, 2024
|
Sell 761 K USD
|
Summy Amy B.
EVP, Chief Marketing Officer |
- 3500
|
217.29 USD |
|
7 months ago
Mar 28, 2024
|
Sell 770 K USD
|
van der Vaart Sandra D
EVP, Chief Legal Officer |
- 3553
|
216.74 USD |
|
8 months ago
Mar 07, 2024
|
Sell 1.1 M USD
|
Schroeder Mark S
EVP, Pres Diagnostics & COO |
- 5048
|
218.45 USD |
|
8 months ago
Mar 07, 2024
|
Sell 49.6 K USD
|
Summy Amy B.
EVP, Chief Marketing Officer |
- 227
|
218.45 USD |
|
8 months ago
Feb 21, 2024
|
Sell 3.96 M USD
|
EISENBERG GLENN A
Chief Financial Officer, EVP |
- 18379
|
215.3661 USD |
|
8 months ago
Feb 21, 2024
|
Sell 1.71 M USD
|
EISENBERG GLENN A
Chief Financial Officer, EVP |
- 7907
|
215.6759 USD |
|
8 months ago
Feb 21, 2024
|
Sell 1.45 M USD
|
EISENBERG GLENN A
Chief Financial Officer, EVP |
- 6665
|
217.5205 USD |
|
8 months ago
Feb 21, 2024
|
Sell 339 K USD
|
EISENBERG GLENN A
Chief Financial Officer, EVP |
- 1553
|
217.9842 USD |
|
8 months ago
Feb 21, 2024
|
Sell 108 K USD
|
DiVincenzo Jonathan P.
EVP, Pres, Central Labs & Intl |
- 500
|
215.4901 USD |
|
9 months ago
Feb 13, 2024
|
Sell 53.7 K USD
|
van der Vaart Sandra D
EVP, Chief Legal Officer |
- 237
|
226.45 USD |
|
9 months ago
Feb 08, 2024
|
Sell 57.5 K USD
|
van der Vaart Sandra D
EVP, Chief Legal Officer |
- 259
|
222.06 USD |
|
9 months ago
Feb 05, 2024
|
Sell 42.6 K USD
|
van der Vaart Sandra D
EVP, Chief Legal Officer |
- 193
|
220.57 USD |
|
1 year ago
Nov 16, 2023
|
Sell 292 K USD
|
Wilkinson Peter J
SVP, Chief Accounting Officer |
- 1384
|
210.713 USD |
|
1 year ago
Aug 08, 2023
|
Sell 1.06 M USD
|
ANDERSON KERRII B
Director |
- 5000
|
211.5665 USD |
|
1 year ago
Jun 29, 2023
|
Sell 50.9 K USD
|
van der Vaart Sandra D
EVP, Chief Legal Officer |
- 212
|
240 USD |
|
1 year ago
May 19, 2023
|
Sell 933 K USD
|
Kirchgraber Paul R
CEO, Covance Drug Development |
- 4300
|
216.9086 USD |
|
1 year ago
May 18, 2023
|
Sell 325 K USD
|
Schroeder Mark S
EVP, Pres Diagnostics & COO |
- 1500
|
216.77 USD |
|
1 year ago
Mar 31, 2023
|
Sell 880 K USD
|
Schroeder Mark S
EVP, President-Diagnostics Lab |
- 3897
|
225.81 USD |
|
1 year ago
Feb 21, 2023
|
Sell 2 M USD
|
Kirchgraber Paul R
CEO, Covance Drug Development |
- 8000
|
250.5844 USD |
|
1 year ago
Feb 14, 2023
|
Sell 76.5 K USD
|
Schroeder Mark S
EVP, President-Diagnostics Lab |
- 309
|
247.63 USD |
|
1 year ago
Feb 07, 2023
|
Sell 53.2 K USD
|
van der Vaart Sandra D
EVP, Chief Legal Officer |
- 219
|
243.01 USD |
|
1 year ago
Feb 07, 2023
|
Sell 99.4 K USD
|
Schroeder Mark S
EVP, President-Diagnostics Lab |
- 409
|
243.01 USD |
|
1 year ago
Feb 03, 2023
|
Sell 43.9 K USD
|
van der Vaart Sandra D
EVP, Chief Legal Officer |
- 173
|
253.9 USD |
|
1 year ago
Feb 03, 2023
|
Sell 82.3 K USD
|
Schroeder Mark S
EVP, President-Diagnostics Lab |
- 324
|
253.9 USD |
|
2 years ago
Nov 08, 2022
|
Sell 260 K USD
|
Schroeder Mark S
EVP, President-Diagnostics Lab |
- 1116
|
232.67 USD |
|
2 years ago
Sep 26, 2022
|
Sell 1.18 M USD
|
EISENBERG GLENN A
Chief Financial Officer, EVP |
- 5627
|
209.294 USD |
|
2 years ago
Sep 26, 2022
|
Sell 1.02 M USD
|
EISENBERG GLENN A
Chief Financial Officer, EVP |
- 4844
|
210.2068 USD |
|
2 years ago
Sep 26, 2022
|
Sell 2.47 M USD
|
EISENBERG GLENN A
Chief Financial Officer, EVP |
- 11699
|
211.1346 USD |
|
2 years ago
Sep 26, 2022
|
Sell 600 K USD
|
EISENBERG GLENN A
Chief Financial Officer, EVP |
- 2830
|
211.8634 USD |
|
2 years ago
Aug 03, 2022
|
Sell 2.85 M USD
|
EISENBERG GLENN A
Chief Financial Officer, EVP |
- 11262
|
253.265 USD |
|
2 years ago
Aug 03, 2022
|
Sell 4.92 M USD
|
EISENBERG GLENN A
Chief Financial Officer, EVP |
- 19338
|
254.259 USD |
|
2 years ago
Aug 03, 2022
|
Sell 382 K USD
|
EISENBERG GLENN A
Chief Financial Officer, EVP |
- 1500
|
254.879 USD |
|
2 years ago
Aug 01, 2022
|
Sell 196 K USD
|
Wilkinson Peter J
SVP, Chief Accounting Officer |
- 757
|
258.6 USD |
|
2 years ago
Aug 01, 2022
|
Sell 2.59 K USD
|
Wilkinson Peter J
SVP, Chief Accounting Officer |
- 10
|
258.705 USD |
|
2 years ago
Aug 01, 2022
|
Sell 467 K USD
|
Wilkinson Peter J
SVP, Chief Accounting Officer |
- 1809
|
258.3125 USD |
|
2 years ago
Jun 07, 2022
|
Bought 10.2 K USD
|
Caveney Brian J
EVP, President of Diagnostics |
+ 42.006
|
242.193 USD |
|
2 years ago
Mar 29, 2022
|
Sell 653 K USD
|
Schroeder Mark S
EVP, President-Diagnostics Lab |
- 2356
|
277.11 USD |
|
2 years ago
Mar 29, 2022
|
Sell 679 K USD
|
van der Vaart Sandra D
EVP, Chief Legal Officer |
- 2449
|
277.11 USD |
|
2 years ago
Mar 25, 2022
|
Sell 156 K USD
|
Williams R Sanders
director: |
- 572
|
272.98 USD |
|
2 years ago
Mar 10, 2022
|
Sell 65.3 K USD
|
Summy Amy B.
EVP, Chief Marketing Officer |
- 249
|
262.21 USD |
|
2 years ago
Feb 16, 2022
|
Bought 159 K USD
|
NEUPERT PETER M
Director |
+ 600
|
264.57 USD |
|
2 years ago
Feb 16, 2022
|
Bought 422 K USD
|
NEUPERT PETER M
Director |
+ 1600
|
263.98 USD |
|
2 years ago
Feb 16, 2022
|
Bought 342 K USD
|
NEUPERT PETER M
Director |
+ 1300
|
262.85 USD |
|
2 years ago
Feb 15, 2022
|
Sell 56.7 K USD
|
Schroeder Mark S
EVP, President-Diagnostics Lab |
- 207
|
273.98 USD |
|
2 years ago
Feb 15, 2022
|
Sell 56.7 K USD
|
van der Vaart Sandra D
EVP, Chief Legal Officer |
- 207
|
273.98 USD |
|
2 years ago
Feb 07, 2022
|
Sell 56.6 K USD
|
Schroeder Mark S
EVP, President-Diagnostics Lab |
- 204
|
277.38 USD |
|
2 years ago
Feb 07, 2022
|
Sell 60.5 K USD
|
van der Vaart Sandra D
EVP, Chief Legal Officer |
- 218
|
277.38 USD |
7. News
Is Labcorp Stock a Good Pick for Your Portfolio Right Now?
Investors are increasingly optimistic about LH due to its partnerships and operational discipline.
zacks.com
- 1 day ago
Labcorp Adds New Capabilities to Global Trial Connect: Stock to Gain?
LH launches new enhancements to Global Trial Connect to streamline site workflow.
zacks.com
- 3 days ago
Labcorp Holdings Inc. (LH) Q3 2024 Earnings Call Transcript
Labcorp Holdings Inc. (NYSE:LH ) Q3 2024 Earnings Conference Call October 24, 2024 9:00 AM ET Company Participants Christin O'Donnell – Vice President-Investor Relations Adam Schechter – Chairman and Chief Executive Officer Glenn Eisenberg – Executive Vice President and Chief Financial Officer Conference Call Participants Ann Hynes – Mizuho Lisa Gill – JPMorgan Michael Cherny – Leerink Partners Patrick Donnelly – Citi Erin Wright – Morgan Stanley David Westenberg – Piper Sandler Jack Meehan – Nephron Research Pito Chickering – Deutsche Bank Andrew Brackmann – William Blair Kevin Caliendo – UBS Elizabeth Anderson – Evercore ISI Eric Coldwell – Baird Stephanie Davis – Barclays John Kim – Bank of America Operator Good day and thank you for standing by. Welcome to the Q3 2024 Labcorp Holdings Earnings Conference Call.
seekingalpha.com
- 3 weeks ago
LH Beats on Q3 Earnings, Raises Revenue Guidance Midpoint, Stock Gains
Labcorp beats on earnings and revenues in the third quarter, entering the fourth half of 2024 with robust momentum.
zacks.com
- 3 weeks ago
Compared to Estimates, Labcorp (LH) Q3 Earnings: A Look at Key Metrics
The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
- 3 weeks ago
Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact
Thursday, Laboratory Corp LH reported third-quarter 2024 adjusted earnings per share of $3.50, up from $3.38 a year ago, beating the consensus of $3.49.
benzinga.com
- 3 weeks ago
Labcorp (LH) Q3 Earnings and Revenues Surpass Estimates
Labcorp (LH) came out with quarterly earnings of $3.50 per share, beating the Zacks Consensus Estimate of $3.48 per share. This compares to earnings of $3.38 per share a year ago.
zacks.com
- 3 weeks ago
Labcorp beats quarterly estimates on diagnostic test demand
Laboratory operator Labcorp on Thursday beat Wall Street estimates for third-quarter profit and revenue, helped by demand for diagnostic tests.
reuters.com
- 3 weeks ago
Labcorp Announces 2024 Third Quarter Results
Updates Full-Year Guidance Results from Continuing Operations for third quarter 2024 versus last year: Revenue: $3.28 billion versus $3.06 billion Diluted EPS: $2.00 versus $2.11 Adjusted EPS: $3.50 versus $3.38 Free Cash Flow: $162 million versus $171 million Updated Full-Year 2024 Guidance: Revenue range of 6.6% to 7.3%; midpoint unchanged Adjusted EPS range of $14.30 to $14.70; midpoint down $0.10, due to the negative impact from weather of approximately $0.15 Free Cash Flow of $850 million to $980 million Announced three new acquisitions/lab management agreements, and closed two acquisitions during the quarter that support growth initiatives BURLINGTON, N.C. , Oct. 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2024 and updated full-year guidance.
prnewswire.com
- 3 weeks ago
Seeking Clues to Labcorp (LH) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Labcorp (LH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
zacks.com
- 3 weeks ago
Labcorp (LH) Reports Next Week: Wall Street Expects Earnings Growth
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 1 month ago
NOWDiagnostics and Labcorp Collaborate to Expand Access to the Only FDA-Marketing Authorized Over-the-Counter Syphilis Test in the U.S.
SPRINGDALE, Ark.--(BUSINESS WIRE)--NOWDiagnostics, Inc. (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, today announced that Labcorp, a global leader of innovative and comprehensive laboratory services, will be the exclusive U.S. distributor of its First To Know® Syphilis Test in professional and healthcare settings. Through Labcorp's extensive distribution network and trusted presence in clinical settings, this collaboration will expand access to the sy.
businesswire.com
- 1 month ago
8. Profile Summary
Laboratory Corporation of America Holdings LH
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 19.7 B
Dividend Yield
0.32%
Description
Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
Contact
358 South Main Street, Burlington, NC, 27215
https://www.labcorp.com
IPO Date
March 29, 1990
Employees
67000
Officers
Ms. Sandra D. van der Vaart J.D.
Executive Vice President, Chief Legal Officer & Corporate Secretary
Mr. Peter J. Wilkinson
Senior Vice President & Chief Accounting Officer
Mr. Mark S. Schroeder
Executive Vice President, President of Diagnostics Laboratories & Chief Operating Officer
Akinbolade Oyegunwa
Executive Vice President and Chief Information & Technology Officer
Ms. Amy B. Summy
Executive Vice President & Chief Marketing Officer
Ms. Anita Z. Graham
Executive Vice President & Chief Human Resources Officer
Mr. Adam H. Schechter
President, Chief Executive Officer & Chairman
Dr. Brian J. Caveney J.D., M.D., M.P.H.
EVice President, President of Early Development Research Laboratories and Chief Medical & Scientific Officer
Christin O'Donnell
Vice President of Investor Relations
Mr. Glenn A. Eisenberg
Chief Financial Officer & Executive Vice President